JP2024536358A5 - - Google Patents

Info

Publication number
JP2024536358A5
JP2024536358A5 JP2024520682A JP2024520682A JP2024536358A5 JP 2024536358 A5 JP2024536358 A5 JP 2024536358A5 JP 2024520682 A JP2024520682 A JP 2024520682A JP 2024520682 A JP2024520682 A JP 2024520682A JP 2024536358 A5 JP2024536358 A5 JP 2024536358A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536358A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/108881 external-priority patent/WO2023011338A1/zh
Publication of JP2024536358A publication Critical patent/JP2024536358A/ja
Publication of JP2024536358A5 publication Critical patent/JP2024536358A5/ja
Pending legal-status Critical Current

Links

JP2024520682A 2021-08-02 2022-07-29 抗cd79b×cd3二重特異性抗体及びその使用 Pending JP2024536358A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110881474.1 2021-08-02
CN202110881474 2021-08-02
PCT/CN2022/108881 WO2023011338A1 (zh) 2021-08-02 2022-07-29 抗CD79b×CD3双特异性抗体及其用途

Publications (2)

Publication Number Publication Date
JP2024536358A JP2024536358A (ja) 2024-10-04
JP2024536358A5 true JP2024536358A5 (cg-RX-API-DMAC7.html) 2025-08-06

Family

ID=85154284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520682A Pending JP2024536358A (ja) 2021-08-02 2022-07-29 抗cd79b×cd3二重特異性抗体及びその使用

Country Status (7)

Country Link
US (1) US20240343799A1 (cg-RX-API-DMAC7.html)
EP (1) EP4382538A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024536358A (cg-RX-API-DMAC7.html)
CN (1) CN117897404A (cg-RX-API-DMAC7.html)
AU (1) AU2022324406B2 (cg-RX-API-DMAC7.html)
CA (1) CA3231174A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023011338A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118667023B (zh) * 2024-07-16 2025-07-15 上海生物制品研究所有限责任公司 一种抗ox40抗体及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
PE20140625A1 (es) * 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
MX386587B (es) * 2014-12-05 2025-03-19 Genentech Inc ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
WO2017177337A1 (en) * 2016-04-15 2017-10-19 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
US20190322741A1 (en) * 2016-06-07 2019-10-24 Macrogenics, Inc. Methods for the Use of CD32B x CD79B-Binding Molecules in the Treatment of Inflammatory Diseases and Disorders
JP2022513338A (ja) * 2018-10-03 2022-02-07 ネペンザ・バイオサイエンシズ・エルエルシー 抗cd79抗体およびその使用
TWI841790B (zh) * 2019-09-30 2024-05-11 大陸商和鉑醫藥(上海)有限責任公司 靶向cd3的抗體、雙特異性抗體及其用途
CR20220166A (es) * 2019-10-18 2022-06-15 Genentech Inc Métodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes
WO2022068809A1 (zh) * 2020-09-29 2022-04-07 信达生物制药(苏州)有限公司 抗cd3抗体以及其用途

Similar Documents

Publication Publication Date Title
JP2024109678A5 (cg-RX-API-DMAC7.html)
JP2023075294A (ja) 抗cd47抗体及びその応用
JP2024522360A5 (cg-RX-API-DMAC7.html)
CN112969476B (zh) 多特异性蛋白分子
JP2021533726A5 (cg-RX-API-DMAC7.html)
JP2021516974A5 (cg-RX-API-DMAC7.html)
JP2021515565A5 (cg-RX-API-DMAC7.html)
CN112135626A (zh) 抗tigit抗体及其用途
JP2021526022A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2019527553A5 (cg-RX-API-DMAC7.html)
JP2020522280A5 (cg-RX-API-DMAC7.html)
CN112955471A (zh) Cd3抗体及其药物用途
CN110536903A (zh) 抗ox40抗体及其用途
CN114502591A (zh) 靶向bcma的抗体、双特异性抗体及其用途
JP2025067915A5 (cg-RX-API-DMAC7.html)
JP2020522281A5 (cg-RX-API-DMAC7.html)
JP2023540526A5 (cg-RX-API-DMAC7.html)
JP2021500916A5 (cg-RX-API-DMAC7.html)
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
JP2017521054A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP2023509373A5 (cg-RX-API-DMAC7.html)
JP2024500512A5 (cg-RX-API-DMAC7.html)